Statins research unfinished saga: desirability versus feasibility

Fisman, Enrique Z.; Adler, Yehuda; Tenenbaum, Alexander
January 2005
Cardiovascular Diabetology;2005, Vol. 4, p8
Academic Journal
Drugs in the same class are generally thought to be therapeutically equivalent because of similar mechanisms of action (the so-called "class effect"). However, statins differ in multiple characteristics, including liver and renal metabolism, half-life, effects on several serum lipid components, bioavailability and potency. Some are fungal derivatives, and others are synthetic compounds. The percentage absorption of an oral dose, amount of protein binding, degree of renal excretion, hydrophilicity, and potency on a weight basis is variable. These differences may be even greater in diabetic patients, who may present diabetes-induced abnormalities in P450 isoforms and altered hepatic metabolic pathways. Thus, it is obvious that head-to-head comparisons between different statins are preferable than trial-to-trial comparisons. Such assessments are of utmost importance, especially in cases in which specific populations with a distinct lipid profile and altered metabolic pathways, like diabetics, are studied. It should be specially pinpointed that patients with metabolic syndrome and diabetes constitute also a special population regarding their atherogenic dyslipidemia, which is usually associated with low HDL-cholesterol, hypertriglyceridemia and predominance of small dense LDL-cholesterol. Therefore, these patients may benefit from fibrates or combined statin/fibrate treatment. This policy is not accomplished since in the real world things are more complex. Trials would require very large sample sizes and long-term follow-up to detect significant differences in myocardial infarction or death between two different statins. Moreover, the fact that new compounds are under several phases of research and development represents an additional drawback for performing the trials. Ideally, head-to-head trials regarding clinically important outcomes should be conducted for all drugs. Nonetheless, the desirability of performing such trials, which epitomize modern evidence-based medicine, is frequently superseded by the feasibility dictated by pragmatic and economic circumstances. In the latter case, in absence of solid systematic documentation of comparable health benefits and long-term safety, both researchers and practicing physicians should allude to the weight of scientific endorsement behind the arguments and seek for the possible strengths and weaknesses intrinsic to each specific study. In any case, conclusions based on surrogate endpoints cannot completely substitute head-to-head comparisons regarding patients' outcome.


Related Articles

  • GPs urged to use statins in every patient with diabetes. Wilkinson, Emma // Pulse;1/12/2004, Vol. 64 Issue 2, p7 

    Reports on British medical authorities' claim that every diabetic patient should be treated with a statin. Reason behind the recommendation; Effect of statin treatment on cardiovascular risk among diabetics.

  • Adherence to Statin Therapy and LDL Cholesterol Goal Attainment by Patients With Diabetes and Dyslipidemia. Parris, Elizabeth S.; Lawrence, David B.; Mohn, Lisa A.; Long, Laura B. // Diabetes Care;Mar2005, Vol. 28 Issue 3, p595 

    OBJECTIVE -- The purpose of this study was to assess the relationship between adherence to statin therapy and LDL cholesterol goal achievement in patients with diabetes and dyslipidemia. RESEARCH DESIGN AND METHODS -- The records of patients being medically treated for dyslipidemia in a managed...

  • Statins under-prescribed in high-risk diabetics. Kelly, Brian // Pulse;10/4/2004, Vol. 64 Issue 39, p20 

    Reports on the underprescription of statins in high-risk diabetes patients in Great Britain. Improvement of secondary prevention.

  • The Mighty Multipurpose Statins. Langbein, W. // Diabetes Interview;May2004, Vol. 13 Issue 5, p18 

    Discusses a study on the effect of cholesterol-lowering statins on risk factors in type 2 diabetes published in the February 2004 issue of the periodical "Diabetes Care." Role of the statin treatment in reducing the cardiovascular complications associated with type 2 diabetes.

  • New trials confirm benefits of aggressive lipid lowering. Alexander, Walter // Drug Topics;4/19/2004, Vol. 148 Issue 8, p30 

    Reports on the topics discussed during the annual meeting of the American College of Cardiology held in New Orleans, Louisiana, which focused entirely on the use of statin and its effects on problematic diabetes patient population. Entry of new drug class targeting smoking and obesity;...

  • High-dose statins potentially overused for some patients with diabetes.  // Cardiology Today;Feb2013, Vol. 16 Issue 2, p24 

    The article reports that a study by researchers from the University of Michigan Health System and the Department of Veterans Affairs (VA) Ann Arbor Healthcare System which suggests that some patients with diabetes are being overtreated with high-dose statins.

  • Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.  // Current Medical Literature: Diabetes;2011, Vol. 28 Issue 4, p137 

    The article discusses a study which confirmed findings on the increased risk of developing new-onset diabetes through intensive-dose statin therapy when compared to moderate-dose statin therapy based on a meta-analysis of the Justification for the use of Statins in Prevention (JUPITER) trial.

  • 'Statins for all' ruing in type 2 diabetes triggers cost fears. Pedder, Cato // Pulse;1/8/2005, Vol. 65 Issue 1, p3 

    Reports on the support of the National Health Services on the prescription of statins for patients with type 2 diabetes in Great Britain. Benefits of statins; Economic impact of the prescription of statins; Increase in the evidence that statins are worthwhile in patients with diabetes.

  • What You Should Know About Statin Use After Menopause.  // Heart Advisor;Apr2012, Vol. 15 Issue 4, p5 

    The article discusses the therapeutic uses of statins. It states that statins are powerful agents in preventing heart attack and they help lower the risk for Alzheimer's disease and age-related decline in lung function. Cardiologist Stephen Nicholas also contents that the overall benefits of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics